Uttroside B

Chemotherapeutic for Liver Cancer

A New Potential Chemotheraputic Agent for the Treatment of Liver Cancer



10th Most Common Cancer

Estimated 39,230 adults in the United States will be diagnosed
every year Short 1-year survival rate

More than 700,000 people worldwide are diagnosed each year

Current Standards of Care


Surgical Hepatectomy or Liver Transplantation

Thermal Ablation
Radiofrequency ablation (RFA) and microwave therapy

Percutaneous ethanol injection
Alcohol is injected directly into the liver tumor

High-energy x-rays or other particles destroy cancer cells

Drug Treatment
tryosine kinase inhibitor antineoplastic agent, Nexavar™

Slide 1 Picture 2

Current Therapy:


Sorafenib Tosylate (Nexavar™) is the only FDA approved drug for the treatment of liver cancer. 2016 Sales exceeded $1 billion.


New Chemotherapeutic Agent:





Uttroside-B increases the cytotoxicity of a variety of liver cancer cell types and has been shown in pre-clinical studies to be 10x
more potent than Sorafenib.

Its cytotoxicity specific to cancerous liver cells.

P Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and capcase activity (apoptosis in liver cancer)

UttroCide-B is:

A natural compound

-Fractionated Saponin derived from S. nigrum
-Small molecule
-Steriod Glycoside

Graph 1 Slide 2
Graph 2 Slide 2
Social media & sharing icons powered by UltimatelySocial